Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Br J Ophthalmol ; 107(10): 1403-1414, 2023 10.
Artigo em Inglês | MEDLINE | ID: mdl-36162969

RESUMO

Combined vision and hearing loss, also known as dual sensory impairment, can occur in several genetic conditions, including ciliopathies such as Usher and Bardet-Biedl syndrome, mitochondrial DNA disorders and systemic diseases, such as CHARGE, Stickler, Waardenburg, Alport and Alstrom syndrome. The retinal phenotype may point to the diagnosis of such disorders. Herein, we aim to provide a comprehensive review of the molecular genetics and clinical features of the most common non-chromosomal inherited disorders to cause dual sensory impairment.


Assuntos
Síndrome de Bardet-Biedl , Surdocegueira , Humanos , Retina , Síndrome de Bardet-Biedl/diagnóstico , Síndrome de Bardet-Biedl/genética , Fenótipo , Biologia Molecular
2.
Br J Ophthalmol ; 105(2): 151-157, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-32269060

RESUMO

Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developed world. Antivascular endothelial growth factor therapy has transformed the management and outcome of neovascular AMD (nAMD), although the need for repeated intravitreal injections-even lifelong-and the related complications, high drug costs, frequent clinic visits and repeated imaging have resulted in an enormous burden both to healthcare systems and patients. The application of gene therapy approaches for sustained delivery of a range of antiangiogenic proteins has the promise of helping to address these aforementioned challenges. A number of early phase clinical trials of gene therapy in nAMD have provided encouraging results, with many more ongoing or anticipated. There remain significant areas of controversy, including regarding the optimal treatment targets, routes of administration and potential safety concerns. In this review we aim to provide an update of the current status of gene therapy for nAMD and briefly discuss future prospects.


Assuntos
Neovascularização de Coroide/terapia , Terapia Genética/métodos , Terapia Genética/tendências , Degeneração Macular Exsudativa/terapia , Ensaios Clínicos como Assunto , Previsões , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA